Yongyuan Zhao
Overview
Explore the profile of Yongyuan Zhao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
45
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burnett G, Yang Y, Aggen J, Pitzen J, Gliedt M, Semko C, et al.
J Med Chem
. 2022 Dec;
66(1):149-169.
PMID: 36533617
Hyperactivation of mTOR kinase by mutations in the PI3K/mTOR pathway or by crosstalk with other mutant cancer drivers, such as RAS, is a feature of many tumors. Multiple allosteric inhibitors...
2.
Lee B, Boyer J, Burnett G, Thottumkara A, Tibrewal N, Wilson S, et al.
Nat Chem Biol
. 2021 Oct;
17(11):1209.
PMID: 34616097
No abstract available.
3.
Lee B, Boyer J, Burnett G, Thottumkara A, Tibrewal N, Wilson S, et al.
Nat Chem Biol
. 2021 Jun;
17(8):925.
PMID: 34188221
No abstract available.
4.
Lee B, Boyer J, Burnett G, Thottumkara A, Tibrewal N, Wilson S, et al.
Nat Chem Biol
. 2021 Jun;
17(10):1065-1074.
PMID: 34168367
The clinical benefits of pan-mTOR active-site inhibitors are limited by toxicity and relief of feedback inhibition of receptor expression. To address these limitations, we designed a series of compounds that...